Herein, for the first time through integrated approaches, we provide a mechanism linking LD accumulation and resistance to conventional CRC chemotherapies such as FOX, involving the acyltransferase LPCAT2. This evidence concerns the gene LPCAT2 and colorectal carcinoma.